Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    87
    ...
ATC Name B/G Ingredients Dosage Form Price
A02BC01 OMEZOL BENTA G Omeprazole - 20mg 20mg Capsule 317,403 L.L
A10BK01 DAPALOZIN G Dapagliflozin propanediol - 10mg 10mg Tablet 1,330,404 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 5g/100ml 5g/100ml Injectable solution 174,062 L.L
C03CA01 LASIMIDE G Furosemide - 20mg/2ml 20mg/2ml Injectable solution 1,300,328 L.L
C09CA03 TABUVAN G Valsartan - 80mg 80mg Tablet, film coated 387,027 L.L
C10AA05 ATORLIP 40 G Atorvastatin (calcium) - 40mg 40mg Tablet, film coated 1,484,626 L.L
G04BE03 SILDENAFIL STRAGEN G Sildenafil - 20mg 20mg Tablet, coated 38,048,630 L.L
J01CR02 AMOKLAVIN BID G Amoxicillin (trihydrate) - 875mg, Clavulanic Acid (potassium) - 125mg 1000mg Tablet, film coated 448,843 L.L
J01GB06 CHEMACIN G Amikacin (sulfate) - 500mg/2ml 500mg/2ml Injectable solution 1,679,803 L.L
L01EA03 NILORA G Nilotinib - 200mg 200mg Capsule, hard 122,185,399 L.L
L02BB03 PROSMIDE G Bicalutamide - 50mg 50mg Tablet, film coated 3,597,914 L.L
M01AB05 DOLONIL G Diclofenac sodium - 75mg/3ml 75mg/3ml Injectable solution 337,880 L.L
N01AH01 FENTANYL MEDIS G Fentanyl (citrate) - 0.5mg/10ml 0.5mg/10ml Injectable solution 1,190,644 L.L
N03AG01 CONVULEX RETARD G Sodium Valproate - 500mg 500mg Tablet, prolonged release 423,310 L.L
N05AX15 REAGILA G Cariprazine HCl - 3mg 3mg Capsule, hard 6,394,003 L.L
P01AB01 METRONOR G Metronidazole - 500mg/100ml 500mg/100ml Injectable solution 5,359,244 L.L
A02BC01 RISEK G Omeprazole - 20mg 20mg Capsule, enteric coated 302,365 L.L
A07EA06 ENTOCORT CIR G Budesonide - 3mg 3mg Capsule, hard, modified release 7,823,588 L.L
A10BK01 DIAFLOZIN G Dapagliflozin - 10mg 10mg Tablet, film coated 2,124,167 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 5g/100ml 5g/100ml Injectable solution 174,062 L.L
C03CA01 URO-CARE G Furosemide - 20mg/2ml 20mg/2ml Injectable solution 1,630,081 L.L
C09CA03 VALSANET G Valsartan - 80mg 80mg Tablet, film coated 479,944 L.L
C10AA05 ATORVA TAD G Atorvastatin - 40mg 40mg Tablet, film coated 1,405,659 L.L
D07XC01 BETA-MICOTER G Betamethasone (dipropionate) - 0.5mg/g, Clotrimazole - 10mg/g Cream 415,951 L.L
J01CR02 ARDINECLAV G Amoxicillin (trihydrate) - 875mg, Clavulanic Acid (potassium) - 125mg 1g Tablet 431,309 L.L
J01GB06 LIKACIN G Amikacin (sulfate) - 500mg/2ml 500mg/2ml Injectable concentrated solution 349,399 L.L
M01AB05 DOLONIL G Diclofenac sodium - 75mg/3ml 75mg/3ml Injectable solution 3,801,155 L.L
N01AH01 FENTANYL PANPHARMA G Fentanyl - 0.5mg/10ml 0.5mg/10ml Injectable solution 1,243,054 L.L
N03AG01 VALPROATE DE SODIUM ARROW LP G Sodium valproate - 500mg 500mg Tablet, coated, scored, prolonged release 253,986 L.L
N05AX15 REAGILA G Cariprazine HCl - 4.5mg 4.5mg Capsule, hard 6,394,003 L.L
    ...
    87
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025